Annual report pursuant to Section 13 and 15(d)

Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details)

v3.22.1
Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Cash $ 31,430
Accounts receivable, net 151,363
Prepaid expenses and other current assets 1,717
Current assets classified as held for sale 184,510
Property and equipment, net 685
Deposits 100,014
Right of use assets 100,116
Non-current assets classified as held for sale 200,815
Accounts payable and checks issued in excess of bank balance 1,108,066 1,911,378
Accrued expenses 341,410 1,642,950
Current portion of right-of-use operating lease obligation 91,166
Current portion of notes payable 168,751
Current liabilities classified as held for sale 1,449,476 3,814,245
Note payable 69,267
Right-of-use operating lease obligation 8,950
Liabilities classified as held for sale 78,217
Revenue from services 216,941 529,066
Cost of services 2,396 5,536
Gross profit 214,555 523,530
Operating expenses 682,659 1,184,226
Other income (expense) 41,695 (35,371)
Gain on sale 11,303,939
Provision for income taxes
Income (loss) from discontinued operations 10,877,530 (696,067)
Advanced Molecular Services Group and Health Technology Solutions Inc [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Cash 31,294
Accounts receivable, net 151,363
Prepaid expenses and other current assets 1,717
Current assets classified as held for sale 184,374
Property and equipment, net 685
Deposits
Right of use assets
Non-current assets classified as held for sale 685
Accounts payable and checks issued in excess of bank balance 726,220
Accrued expenses 1,308,283
Current portion of right-of-use operating lease obligation
Current portion of notes payable 168,751
Current liabilities classified as held for sale 2,203,254
Note payable 69,267
Right-of-use operating lease obligation
Liabilities classified as held for sale 69,267
Revenue from services [1] 216,941 528,624
Cost of services 2,386 5,536
Gross profit 214,555 523,088
Operating expenses (551,296) (1,045,410)
Other income (expense) (9,577) (84,129)
Gain on sale 11,303,939
Provision for income taxes
Income (loss) from discontinued operations 10,957,621 (606,451)
EPIC Reference Labs, Inc. [Member]    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Cash 136
Accounts receivable, net
Prepaid expenses and other current assets
Current assets classified as held for sale 136
Property and equipment, net
Deposits 100,014
Right of use assets 100,116
Non-current assets classified as held for sale 200,130
Accounts payable and checks issued in excess of bank balance 1,108,066 1,185,158
Accrued expenses 341,410 334,667
Current portion of right-of-use operating lease obligation 91,166
Current portion of notes payable
Current liabilities classified as held for sale 1,449,476 1,610,991
Note payable
Right-of-use operating lease obligation 8,950
Liabilities classified as held for sale 8,950
Revenue from services 442
Cost of services
Gross profit 442
Operating expenses 131,363 138,816
Other income (expense) 51,272 48,758
Gain on sale
Provision for income taxes
Income (loss) from discontinued operations $ (80,091) $ (89,616)
[1] Revenue from services includes related party revenue of $0.2 million and $0.2 million, respectively.